

PRODUCT DATA SHEET

Bioworld Technology CO., Ltd.



Connexin 45 (N361) Peptide

Cat No.: BS3470P

Background

Connexin proteins share a common topology of four transmembrane α -helical domains, two extracellular loops, a cytoplasmic loop and cytoplasmic N- and C-termini. Many of the key functional differences arise from specific amino acid substitutions in the most highly conserved domains, the transmembrane and extracellular regions. Each of the approximately 20 connexin isoforms produces channels with distinct permeabilities and electrical and chemical sensitivities; therefore, one connexin usually cannot fully substitute for another. Consequently, a wide variety of malignant phenotypes associate with decreased connexin expression and gap junction communication, dependent on the particular connexin that is effected. For instance, down-regulation of connexin 45 in the left ventricle associates with end-stage heart failure due both to ischaemic cardiomyopathy and idiopathic dilated cardiomyopathy.

Swiss-Prot

P36383

Applications

Blocking

Specificity

This peptide can be used with studies using BS3470 Connexin 45 (N361) pAb.

Purification & Purity

Synthetic peptide Connexin 45 (N361). (Note: the amino acid sequence is proprietary). The purity is > 98%.

Product

1 mg/ml in DI water.

Storage & Stability

Store at 4 °C short term. Aliquot and store at -20 °C long term. Avoid freeze-thaw cycles.

Research Use

For research use only, not for use in diagnostic procedure.

Bioworld Technology, Inc.
1660 South Highway 100, Suite 500 St. Louis Park, MN
55416, USA. Email: info@bioworld.com
Tel: 6123263284 Fax: 6122933841

Bioworld technology, co, Ltd.
No 9, weidi road Qixia District Nanjing, 210046,
P, R.China. Email: info@biogot.com
Tel: +86-025-68037686 Fax: +86-025-68035151